and Group subsidiary Orano Med have announced a partnership to enhance the development of next-generation radioligand therapies (RLTs) for rare cancers. The companies plan to invest in a new entity, operating under the brand Orano Med, which focuses on the discovery, design and development of RLTs based on lead-212 (212Pb) alpha-emitting isotopes. The gold standard of business intelligence.
Sanofi’s €300m ($325m) equity investment will give it a 16% stake in the new entity valued at €1.9bn. This investment is expected to strengthen Orano Med further and allow the company to expedite its pipeline development, leveraging its lead-212-based therapies discovery and development capabilities.
The strategic partnership follows Sanofi’s with Orano Med and RadioMedix, focusing on the advanced project AlphaMedix. Sanofi CEO Paul Hudson stated: “This collaboration is part of a broader effort to strengthen our ties within the scientific community, both in France and globally, to advance the development of cutting-edge treatments for patients.” Access the most comprehensive Company Profiles on the market, powered by GlobalData.
Save hours of research. Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles.
However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form As a potent alpha-emitting radioisotope, Pb is .